Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial
DOI:
https://doi.org/10.2340/actadv.v103.4881Keywords:
mycosis fungoides, chlormethine gel, response rates, prior treatment, posthoc analysisAbstract
Abstract is missing (Short communication)
Downloads
References
Valchlor (mechlorethamine gel) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc. [Accessed 28 September 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202317s009lbl.pdf.
Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013; 149: 25-32.
https://doi.org/10.1001/2013.jamadermatol.541 DOI: https://doi.org/10.1001/2013.jamadermatol.541
Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides. Dermatology 2022; 238: 347-357.
https://doi.org/10.1159/000516138 DOI: https://doi.org/10.1159/000516138
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv30-40.
https://doi.org/10.1093/annonc/mdy133 DOI: https://doi.org/10.1093/annonc/mdy133
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. Eur J Cancer 2017; 77: 57-74.
https://doi.org/10.1016/j.ejca.2017.02.027 DOI: https://doi.org/10.1016/j.ejca.2017.02.027
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Primary cutaneous lymphoma. Version 2.2022. 2022. [Accessed 28 September 2022]. Available from: https://www.nccn.org/professionals/physician_gls/default_nojava.aspx.
Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges 2021; 19: 1057-1059.
https://doi.org/10.1111/ddg.14462 DOI: https://doi.org/10.1111/ddg.14462
Papadavid E, Koumourtzis M, Nikolaou V, Lampadaki K, Marinos L, Patsatsi A, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol 2022; 36: 1751-1757.
https://doi.org/10.1111/jdv.18183 DOI: https://doi.org/10.1111/jdv.18183
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol 2021; 22: 407-414.
https://doi.org/10.1007/s40257-021-00591-x DOI: https://doi.org/10.1007/s40257-021-00591-x
Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke CD, et al. The optimal use of chlormethine gel for mycosis fungoides: an expert consensus from Germany, Austria and Switzerland (DACH region). J Dtsch Dermatol Ges 2022; 20: 579-586.
https://doi.org/10.1111/ddg.14688 DOI: https://doi.org/10.1111/ddg.14688
Published
How to Cite
License
Copyright (c) 2023 Chalid Assaf, Christiane Querfeld, Marta Scandurra, Marco Turini, Julia J. Scarisbrick
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
